| Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor … G Dranoff, E Jaffee, A Lazenby, P Golumbek, H Levitsky, K Brose, ... Proceedings of the National Academy of Sciences 90 (8), 3539-3543, 1993 | 3432 | 1993 |
| The Central Role of CD4+ T Cells in the Antitumor Immune Response K Hung, R Hayashi, A Lafond-Walker, C Lowenstein, D Pardoll, ... The Journal of experimental medicine 188 (12), 2357-2368, 1998 | 1721 | 1998 |
| Role of LAG-3 in regulatory T cells CT Huang, CJ Workman, D Flies, X Pan, AL Marson, G Zhou, EL Hipkiss, ... Immunity 21 (4), 503-513, 2004 | 1647 | 2004 |
| Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens AYC Huang, P Golumbek, M Ahmadzadeh, E Jaffee, D Pardoll, H Levitsky Science 264 (5161), 961-965, 1994 | 1529 | 1994 |
| Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy CH Ries, MA Cannarile, S Hoves, J Benz, K Wartha, V Runza, ... Cancer cell 25 (6), 846-859, 2014 | 1378 | 2014 |
| Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response ER Fearon, DM Pardoll, T Itaya, P Golumbek, HI Levitsky, JW Simons, ... Cell 60 (3), 397-403, 1990 | 1263 | 1990 |
| Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen KY Lin, FG Guarnieri, KF Staveley-O'Carroll, HI Levitsky, JT August, ... Cancer research 56 (1), 21-26, 1996 | 1218 | 1996 |
| Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4 PT Golumbek, AJ Lazenby, HI Levitsky, LM Jaffee, H Karasuyama, ... Science 254 (5032), 713-716, 1991 | 951 | 1991 |
| Induction of antigen-specific T cell anergy: an early event in the course of tumor progression K Staveley-O’Carroll, E Sotomayor, J Montgomery, I Borrello, L Hwang, ... Proceedings of the National Academy of Sciences 95 (3), 1178-1183, 1998 | 921 | 1998 |
| Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte … JW Simons, B Mikhak, JF Chang, AM DeMarzo, MA Carducci, M Lim, ... Cancer research 59 (20), 5160-5168, 1999 | 565 | 1999 |
| Bioactivity of Autologous Irradiated Renal Cell Carcinoma Vaccines Generated by ex Vivo Granulocyte-Macrophage Colony-stimulating Factor Gene Transfer JW Simons, EM Jaffee, CE Weber, HI Levitsky, WG Nelson, MA Carducci, ... Cancer research 57 (8), 1537-1546, 1997 | 541 | 1997 |
| Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40 EM Sotomayor, I Borrello, E Tubb, FM Rattis, H Bien, Z Lu, S Fein, ... Nature medicine 5 (7), 780-787, 1999 | 524 | 1999 |
| High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease L Luznik, J Bolaños-Meade, M Zahurak, AR Chen, BD Smith, R Brodsky, ... Blood, The Journal of the American Society of Hematology 115 (16), 3224-3230, 2010 | 478 | 2010 |
| Depleting tumor-specific Tregs at a single site eradicates disseminated tumors A Marabelle, H Kohrt, I Sagiv-Barfi, B Ajami, RC Axtell, G Zhou, ... The Journal of clinical investigation 123 (6), 2447-2463, 2013 | 469 | 2013 |
| Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. TC Wu, FG Guarnieri, KF Staveley-O'Carroll, RP Viscidi, HI Levitsky, ... Proceedings of the National Academy of Sciences 92 (25), 11671-11675, 1995 | 448 | 1995 |
| Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines G Zhou, CG Drake, HI Levitsky Blood 107 (2), 628-636, 2006 | 344 | 2006 |
| Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity DJ Morgan, HTC Kreuwel, S Fleck, HI Levitsky, DM Pardoll, LA Sherman The Journal of Immunology 160 (2), 643-651, 1998 | 310 | 1998 |
| In vivo cross-priming of MHC class I–restricted antigens requires the TAP transporter AYC Huang, AT Bruce, DM Pardoll, HI Levitsky Immunity 4 (4), 349-355, 1996 | 301 | 1996 |
| Cell polarity: an examination of its behavioral expression and its consequences for polymorphonuclear leukocyte chemotaxis. SH Zigmond, HI Levitsky, BJ Kreel The Journal of cell biology 89 (3), 585-592, 1981 | 298 | 1981 |
| Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance G Zhou, HI Levitsky The Journal of Immunology 178 (4), 2155-2162, 2007 | 268 | 2007 |
